In short
Azenosertib, also known as ZN-c3, is an innovative drug currently being studied in clinical trials for various types of cancer. This article explores the ongoing research into Azenosertib's potential as a treatment for uterine serous carcinoma, triple-negative breast cancer, pancreatic cancer, and other solid tumors. We'll look at how it works, its combination with other drugs, and what these trials mean for cancer patients.
At a glance
- Drug Name
- Azenosertib (ZN-c3)
- Drug Class
- Wee1 inhibitor
- Administration
- Oral tablets
- Cancer Types Studied
- Uterine Serous Carcinoma, Triple-Negative Breast Cancer, Pancreatic Cancer, HER2-positive solid tumors
- Combination Therapies
- Carboplatin, Pembrolizumab, Trastuzumab Deruxtecan
- Trial Phases
- Phase I/II
- Primary Outcomes
- Safety, tolerability, maximum tolerated dose, pharmacodynamic effects
- Secondary Outcomes
- Objective response rate, progression-free survival, duration of response
What is Azenosertib?
Azenosertib, also known as ZN-c3 or KP-2638, is a new type of cancer drug called a WEE1 inhibitor. It belongs to a class of medications known as kinase inhibitors. Azenosertib is currently being studied in clinical trials to treat various types of cancer. It's important to note that the U.S. Food and Drug Administration (FDA) has not yet approved Azenosertib for general use, which means it's still considered an experimental treatment.
How Does Azenosertib Work?
Azenosertib works by inhibiting (blocking) a protein called WEE1. This protein plays a crucial role in regulating cell division. By inhibiting WEE1, Azenosertib can make cancer cells more vulnerable to chemotherapy drugs, potentially leading to the death of these harmful cells. This mechanism of action is particularly interesting to researchers because it could potentially enhance the effectiveness of other cancer treatments.
Cancers Treated with Azenosertib
Azenosertib is being studied for use in several types of cancer, including:
- Triple-negative breast cancer: This is a type of breast cancer that doesn't respond to hormonal therapy or medicines that target HER2 protein.
- Uterine serous carcinoma: A rare and aggressive type of uterine cancer.
- Pancreatic cancer: Specifically, locally advanced or metastatic pancreatic ductal adenocarcinoma.
- Gastric (stomach) and gastroesophageal junction cancer: Particularly those that are HER2-positive and have cyclin E amplification.
Clinical Trials and Research
Several clinical trials are currently underway to study Azenosertib:
- A trial called ZAP-IT is studying Azenosertib in combination with carboplatin and pembrolizumab for metastatic triple-negative breast cancer.
- Another study is looking at how Azenosertib affects tumor cells in persistent or recurrent uterine serous carcinoma.
- A trial is testing Azenosertib along with other targeted therapies in patients with pancreatic cancer.
- Researchers are also studying the combination of Azenosertib with trastuzumab deruxtecan in treating HER2-positive gastric or gastroesophageal junction cancer and other HER2-positive solid tumors.
Administration and Dosage
Azenosertib is typically given as an oral medication (taken by mouth) in the form of tablets. The dosage and schedule can vary depending on the specific clinical trial and the type of cancer being treated. In some studies, it's given once daily for several days in a row, followed by a break, in cycles that repeat every 21 days. However, the exact dosing schedule may be adjusted based on how well a patient tolerates the medication and how their cancer responds to treatment.
Potential Side Effects
As Azenosertib is still in clinical trials, the full range of potential side effects is not yet known. Researchers are closely monitoring patients for any adverse reactions. Common side effects of cancer treatments can include fatigue, nausea, and changes in blood cell counts. Patients in clinical trials are regularly monitored through blood tests, scans, and other assessments to check for any concerning side effects.
Future Prospects
The development of Azenosertib represents an exciting new approach in cancer treatment. By targeting the WEE1 protein, it may offer a new way to combat cancer cells, especially when combined with other treatments. However, it's important to remember that as an experimental drug, more research is needed to fully understand its effectiveness and safety. The ongoing clinical trials will provide crucial information about how well Azenosertib works for different types of cancer and what role it might play in future cancer treatments.